SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell…
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio…
New clinical data from Phio's on-going Phase 1b trial to be presentedMarlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio…
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute…
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20…
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults…
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults…
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults…
London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies…
SHANGHAI, Oct. 21, 2024 /PRNewswire/ -- Sanyou Bio provides oneClick+ antigen one-stop solution, from antigen analysis to personalized preparation, to…